Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Income from Continuing Operations (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Income from Continuing Operations readings, the most recent being 2954000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 35.92% year-over-year to 2954000.0, compared with a TTM value of 16586000.0 through Dec 2025, up 17.01%, and an annual FY2025 reading of 16586000.0, up 17.01% over the prior year.
  • Income from Continuing Operations hit 2954000.0 in Q4 2025 for Lisata Therapeutics, up from 4249000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2954000.0 in Q4 2025, with the low at 6187000.0 in Q1 2023.
  • Median Income from Continuing Operations over the past 3 years was 4827000.0 (2024), compared with a mean of 4784250.0.
  • The sharpest move saw Income from Continuing Operations dropped 25.25% in 2024, then surged 35.92% in 2025.
  • Year by year, Income from Continuing Operations stood at 5365000.0 in 2023, then increased by 14.07% to 4610000.0 in 2024, then skyrocketed by 35.92% to 2954000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 2954000.0, 4249000.0, and 4659000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.